We investigated the immunoregulatory effects of ibudilast, a nonselective phosphodiesterase inhibitor, at a clinically applicable dose (60 mg/day p.o. for four weeks) in multiple sclerosis (MS) patients. Sensitive real-time PCR for quantifying cytokine mRNA in the blood CD4- cells revealed that the ibudilast monotherapy significantly reduced tumour necrosis factor-a and interferon (IFN)-g mRNA and the IFN-g/interleukin-4 mRNA ratio, suggesting a shift in the cytokine profile from Th1 toward Th2 dominancy. In a flow cytometric analysis, natural killer T cells, which have been reported to relate to Th2 responses in MS and its animal model (experimental autoimmune encephalomyelitis), increased significantly after the therapy. None of the significant immunological changes were seen in healthy subjects or untreated MS patients. Ibudilast may be a promising therapy for MS and its clinical effects warrant further study.
Link H.The cytokine storm in multiple sclerosis . Mult Scler1998; 4: 12-15 .
2.
Misu T , Onodera H , Fujihara K , Matsushima K , Yoshie O , Okita Net al.Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling . J Neuroimmunol2001; 114: 207-212 .
3.
Rieckmann P , Albrecht M , Kitze B , Weber T , Tumani H , Broocks Aet al.Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis . Neurology1994; 44: 1523-1526 .
4.
Vartanian T , Li Y , Zhao M , Stefansson K.Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis . Mol Med1995; 1: 732-743 .
5.
Selmaj K , Raine CS.Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue . Ann NY Acad Sci1988; 540: 568-570 .
6.
Araki M , Kondo T , Gumperz JE , Brenner MB , Miyake S , Yamamura T.Th2 bias of CD4- NKT cells derived from multiple sclerosis in remission . Int Immunol2003; 15: 279-288 .
7.
Yoshimura T , Nagao T , Nakao T , Watanabe S , Usami E , Kobayashi Jet al.Modulation of Th1- and Th2-like cytokine production from mitogen-stimulated human peripheral blood mononuclear cells by phosphodiesterase inhibitors . Gen Pharmacol1998; 30: 175-180 .
8.
Sommer N , Loschmann PA , Northoff GH , Weller M , Steinbrecher A , Steinbach JPet al.The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis . Nat Med1995; 1: 244-248 .
9.
Sommer N , Martin R , McFarland HF , Quigley L , Cannella B , Raine CSet al.Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease . J Neuroimmunol1997; 79: 54-61 .
10.
Suzumura A , Nakamuro T , Tamaru T , Takayanagi T.Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors . Mult Scler2000; 6: 56-58 .
11.
Aizawa T , Hasegawa T , Gotoh F , Katsunuma H , Araki G , Nara Met al.Clinical evaluation of KC-404 in the chronic stage of cerebrovascular disorders . Kiso-to-Rinsho (Clin Rep)1984; 18: 5409-5433 (in Japanese).
12.
Shinohara Y , Kusunoki T , Nakashima M.Clinical efficacy of ibudilast on vertigo and dizziness observed in patients with cerebral infarction in the chronic stage-a double-blind, randomized, placebo-controlled trial with a run-in period . Shinnkeitiryougaku (Neurol Ther)2002; 19: 177-187 (in Japanese, English abstract).
13.
Takahashi T , Kawakami Y , Takishima T , Mue S , Kobayashi S , Nemoto Tet al.Clinical evaluation of KC-404, a new anti-asthmatic agent, in the treatment of bronchial asthma . Rinsho-Hyoka (Clin Eval)1986; 14: 373-407 (in Japanese).
14.
Kishi Y , Ohta S , Kasuya N , Sakita S , Ashikaga T , Isobe M.Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall . Cardiovasc Drug Rev2001; 19: 215-225 .
15.
Fujimoto T , Sakoda S , Fujimura H , Yanagihara T.Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental auto-immune encephalomyelitis in Dark August rats . J Neuroimmunol1999; 95: 35-42 .
16.
Rieckmann P , Weber F , Gunther A , Martin S , Bitsch A , Broocks Aet al.Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis . J Neuroimmunol1996; 64: 193-200 .
17.
Yoshikawa M , Suzumura A , Tamaru T , Takayanagi T , Sawada M.Effects of phosphodiesterase inhibitors on cytokine production by microglia . Mult Scler1999; 5: 126-133 .
18.
Ekholm D , Hemmer B , Gao G , Vergelli M , Martin R , Manganiello V.Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein . J Immunol1997; 159: 1520-1529 .
19.
Bielekova B , Lincoln A , McFarland H , Martin R.Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1- mediated autoimmune diseases . J Immunol2000; 164: 1117-1124 .
20.
Suzumura A , Ito A , Yoshikawa M , Sawada M.Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS . Brain Res1999; 837: 203-212 .
21.
Lantz O , Bendelac A.An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4-and CD4-8- T cells in mice and humans . J Exp Med1994; 180: 1097-1106 .
22.
Bendelac A , Rivera MN , Park SH , Roark JH.Mouse CD1- specific NK1 T cells: development, specificity, and function . Annu Rev Immunol1997; 15: 535-562 .
23.
Illes Z , Kondo T , Newcombe J , Oka N , Tabira T , Yamamura T.Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy . J Immunol2000; 164: 4375-4381 .
24.
Miyamoto K , Miyake S , Yamamura T.A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells . Nature2001; 413: 531-534 .
